Track MapLight Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MapLight Therapeutics, Inc. MPLT · Stock Open MapLight Therapeutics, Inc. in new tab

7.25 USD
EPS
-6.25
P/B
0.95
ROE
-111.55
Target Price
26.54 USD
Loading chart...
Key Metrics
Earnings dateDec. 3, 2026
EPS-6.25
Book Value7.67
Price to Book0.95
Debt/Equity0.57
% Insiders52.388%
Estimates
Forward P/E-2.12
Forward EPS-3.42
Target Mean Price26.54

DCF valuation

Model fair value for MapLight Therapeutics, Inc. (MPLT)
Result
Sign in to run the valuation for MPLT.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 26.54 USD (low 13.00, high 43.00)
Low 13.00
Mean 26.54
High 43.00
Price 7.25
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

MapLight Therapeutics, Inc. Logo MapLight Therapeutics, Inc. Analysis (MPLT)

US Healthcare Official Website Stock

Is MapLight Therapeutics, Inc. a good investment? MapLight Therapeutics, Inc. (MPLT) is currently trading at 7.25 USD. Market analysts have a consensus price target of 26.54 USD. This suggests a potential upside from current levels.

Earnings Schedule: MapLight Therapeutics, Inc. is expected to release its next earnings report on Dec. 3, 2026. The market consensus estimate for Forward EPS is -3.42.

Investor FAQ

Does MapLight Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is MapLight Therapeutics, Inc.?

MapLight Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Dec. 3, 2026. The company currently has a trailing EPS of -6.25.

Company Profile

MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders. The company also develops platform identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. The company was formerly known as Alvarado Therapeutics, Inc. and changed its name to MapLight Therapeutics, Inc. in August 2019. MapLight Therapeutics, Inc. was incorporated in 2018 and is based in Redwood City, California.

Exchange Ticker
NASDAQ MPLT
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion